Analysis of durability of response to thalidomide treatment for relapsed myeloma patients

被引：3
|
作者：
Myers, B [1 ]
Dolan, G [1 ]
机构：
[1] Univ Nottingham Hosp, Queens Med Ctr, Dept Clin & Lab Haematol, Nottingham NG7 2UH, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2002年 / 118卷 / 01期
关键词：
thalidomide; myeloma; therapy; duration;
D O I：
10.1046/j.1365-2141.2002.03576_4.x
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：347 / 347
页数：1
相关论文
共 50 条
  • [1] Durability of response with thalidomide therapy for relapsed multiple myeloma
    Myers, B
    Jones, SG
    Dolan, G
    7TH ANNUAL MEETING OF THE EUROPEAN HAEMATOLOGY ASSOCIATION, 2002, : 259 - 262
  • [2] Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma
    Kumar, S
    Gertz, MA
    Dispenzieri, A
    Lacy, MQ
    Geyer, SM
    Iturria, NL
    Fonseca, R
    Hayman, SR
    Lust, JA
    Kyle, RA
    Greipp, PR
    Witzig, TE
    Rajkumar, SV
    MAYO CLINIC PROCEEDINGS, 2003, 78 (01) : 34 - 39
  • [3] Thalidomide treatment of resistant or relapsed multiple myeloma patients
    Hus, M
    Dmoszynska, A
    Soroka-Wojtaszko, M
    Jawniak, D
    Legiec, W
    Ciepnuch, H
    Hellmann, A
    Wolska-Smolen, T
    Skotnicki, A
    Manko, J
    HAEMATOLOGICA, 2001, 86 (04) : 404 - 408
  • [4] Thalidomide in the treatment of relapsed multiple myeloma
    Rajkumar, SV
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Lust, JA
    Witzig, TE
    Kyle, RA
    Gertz, MA
    Greipp, PR
    MAYO CLINIC PROCEEDINGS, 2000, 75 (09) : 897 - 901
  • [5] Thalidomide in the treatment of relapsed and refractory myeloma.
    Rajkumar, SV
    Fonseca, R
    Dispenzieri, A
    Lacy, MQ
    Witzig, TE
    Lust, JA
    Kyle, RA
    Gertz, MA
    Greipp, PR
    BLOOD, 1999, 94 (10) : 316A - 316A
  • [6] Thalidomide for the treatment of relapsed and refractory multiple myeloma
    Cool, RM
    Herrington, JD
    PHARMACOTHERAPY, 2002, 22 (08): : 1019 - 1028
  • [7] Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF
    Pitini, V
    Teti, D
    Arrigo, C
    Aloi, G
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 119 (01) : 275 - 275
  • [8] Durable response to thalidomide in relapsed/refractory multiple myeloma (MM).
    Raza, SN
    Veksler, Y
    Sabir, T
    Li, ZJ
    Anderson, L
    Jagannath, S
    BLOOD, 2000, 96 (11) : 168A - 169A
  • [9] TREATMENT RESPONSE IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA PATIENTS
    Ioana, I.
    Liviu, C.
    Maria, C.
    Claudiu, I.
    Maria, I.
    Mihai, I.
    Dacian, O.
    Ovidiu, P.
    Cristina, S.
    Despina, C.
    Hortensia, I.
    HAEMATOLOGICA, 2013, 98 : 614 - 614
  • [10] Prolonged progression free survival does not relate to quality of response to treatment with thalidomide in patients with relapsed multiple myeloma (MM)
    Quach, Hang
    Prince, Miles H.
    Mileshkin, Linda
    Seymour, John F.
    Westerman, David
    Milner, Alvin D.
    BLOOD, 2007, 110 (11) : 798A - 798A
12345